---
format:
  revealjs:
    touch: true
    controls: true
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: false
    incremental: true
    multiplex: true
    chalkboard: true
    theme: [default, custom.scss]
bibliography: references.bib
---

## Principles and Complexity of Antifungal Therapy {background-image="aspergillus.png"}

<br> <br>

<br>

<br>

<br> <br>

<left>**Russell E. Lewis, Pharm.D., FCCP** <br> Associate Professor of Medicine, Infectious Diseases <br> Department of Medical and Surgical Sciences <br> Infectious Diseases Unit- IRCCS S. Orsola University Hospitals <br> Alma Mater Studiorum Università di Bologna <br> Bologna, Italy</left>

## Disclosures

<br>

-   **Research funding:** Merck & Co Inc., Gilead Sciences
-   **Speaking:** Avir, Gilead
-   **Consultancy:** F2G, Scynexis, Gilead Sciences, Cidara Therapeutics

## Objectives

<br>

-   Identify common pharmacological factors that affect treatment success
-   Discuss how uncertainty in antifungal drug dosing can be addressed through PK/PD principles
-   Recognise common toxicity problems with antifungals and the general management approach

## Antifungal timeline {.smaller}

<br>

![](timeline2.png){fig-align="left"}

## Current antifungal targets {.smaller}

![](DTR.png){fig-align="center" width="800"}

::: aside
Figure created by R. Lewis using biorender.com
:::

## What factors drive the success of antifungal therapy? {.smaller}

![](PKPD.png){fig-align="center" width="650"}

::: aside
[@theuretzbacher2012]
:::

## The PK/PD index {.smaller}

![](PKPD_combined.png){fig-align="center" width="1200"}

::: aside
[@theuretzbacher2012]
:::

## Antifungal PK/PD targets associated with efficacy {.smaller}

<br>

| **A**ntifungal       | Preclinical efficacy target | Clinical efficacy target                                                                         |
|----------------------|-----------------------------|--------------------------------------------------------------------------------------------------|
| Amphotericin B (AMB) | C~max~/MIC; AUC~0-24~/MIC   | Not established                                                                                  |
| Liposomal AMB        | AUC~0-24~/MIC               | Not established                                                                                  |
| Flucytosine (5FC)    | Time \> MIC                 | \>20-45% Time \>MIC                                                                              |
| Fluconazole          | AUC~0-24~/MIC               | *f*AUC~0-24~/MIC \< 25-100; <br>C~min~ 10-15 mg/L                                                |
| Itraconazole         | AUC~0-24~/MIC               | C~min~ \> 0.5 mg/L (prophylaxis); <br> C~min~\> 1 mg/L (treatment)                               |
| Voriconazole         | AUC~0-24~/MIC               | *f*AUC~0-24~/MIC 25-50; <br> C~min~ \> 1 mg/L or C~min~/MIC 2-5 mg/L                             |
| Posaconazole         | AUC~0-24~/MIC               | *f*AUC~0-24~/MIC 25-50; <br> prophylaxis C~min~ \> 0.5-0.7 mg/L; <br> treatment C~min~ \> 1 mg/L |
| Isavuconazole        | AUC~0-24~/MIC               | *f*AUC~0-24~/MIC 25-50                                                                           |
| Echinocandins        | AUC~0-24~/MIC               | AUC/MIC \> 3000                                                                                  |

::: aside
*f- free (non-protein bound) drug*

[@Lewis2021]
:::

## What factors drive the success of antifungal therapy?

![](PKPD.png){fig-align="center" width="650"}

::: aside
[@theuretzbacher2012]
:::

## What factors drive the success of antifungal therapy?

![](PKPD2.png){fig-align="center" width="650"}

::: aside
[@theuretzbacher2012]
:::

## Intrinsic activity of antifungals

![](antifungal_spectrum%20(1).png){fig-align="center"}

<br>

## Acquired antifungal resistance

![](PKPD3.png){fig-align="center" width="650"}

::: aside
[@theuretzbacher2012]
:::

## Acquired resistance mechanisms and detection

![](acquired_reisstance.png){fig-align="center" width="800"}

::: aside
Figure: Created by R. Lewis using biorender.com
:::

## Antifungal susceptibility testing- Where do we stand? {background-image="MIC_microbroth_dilution.png"}

<br>

-   **Reference methods for yeasts and moulds have been developed by:**

    -   European Committee on Antimicrobial Susceptibility Testing (EUCAST)

    -   Clinical Laboratory Standards Institute (CLSI)

        -   Fungal species and drug-specific susceptibility breakpoints for *Candida* and *Aspergillus* spp.

-   **Some commercial phenotypic and molecular tests are approved for detection of common antifungal resistance mechanisms**

-   **Need for "in house" antifungal susceptibility testing will increase with the introduction of new antifungals**

    <br>

::: aside
[@Wiederhold2021]
:::

## Pharmacokinetic factors

![](PKPD_PK1.png){fig-align="center" width="650"}

::: aside
[@theuretzbacher2012]
:::

## Antifungal tissue distribution studies

![](af_distribution.png){fig-align="center" width="650"}

::: aside
[@felton2014b]
:::

## Pharmacokinetic factors

![](PKPD_PK2.png){fig-align="center" width="650"}

::: aside
[@theuretzbacher2012]
:::

## Antifungal pharmacokinetics in the critically-ill

![](critical%20illness.png){fig-align="center" width="800"}

::: aside
[@roberts2014e]

Vd- volume of distribution; Cl- clearance
:::

## Pharmacokinetic complexity of voriconazole

<br>

![](voripk.png){fig-align="center"}

::: aside
[@trifilio2014]\]
:::

## Triazole therapeutic drug monitoring during <br> antifungal treatment {.smaller}

<br>

| Reference          | Fluconazole <br> (mg/L)         | Itraconazole <br>(mg/L) | Voriconazole <br>(mg/L) | Posaconazole<br>(mg/L) | Isavuconazole<br>(mg/L) |
|--------------------|---------------------------------|-------------------------|-------------------------|------------------------|-------------------------|
| [@Gómez-López2020] | Not routine                     | 1-4 (HPLC)              | 1-6                     | \>1                    | Not routine             |
| [@Ashbee2014]      | Not routine                     | 0.5-1 (HPLC)            | 1-6                     | \>1                    | Not routine             |
| [@Scodavolpe2014]  | AUC/MIC \> 25; <br>C~min~ 10-15 | \>1-2 (HPLC)            | 1-4                     | 0.5-1.5                | Not routine             |
| [@Chau2014]        | Not routine                     | 0.5-1 (HPLC)            | 1-6                     | \>1                    | Not routine             |
| [@Abdul-Aziz2020]  | Not routine                     | \>0.5-1 (HPLC)          | 2-6                     | \>1                    | Not routine             |
| [@Chau2021]        | Not routine; <br>C~min~ \>11    | 1-4 (HPLC)              | 1-5.5                   | \>1                    | Not routine             |

## Toxicity

![](PKPD_drug%20interactions.png){fig-align="center" width="650"}

## Common antifungal toxicities

<br>

![](toxicities.png){fig-align="center"}

::: aside
[@Lewis2011805; @johnson2021]
:::

## Antifungal toxicities: Acute vs. Chronic {.smaller}

<br>

![](strategy.png){fig-align="center" width="300"}

## Triazole drug interactions

![](DI.png){fig-align="center"}

::: aside
[@andes2016; @bruggemann2009a]
:::

## What factors drive the success of antifungal therapy? {.smaller}

![](PKPD.png){fig-align="center" width="650"}

::: aside
[@theuretzbacher2012]
:::

## Summary

<br>

-   Pharmacokinetic and pharmacodynamic factors need to be considered when selecting antifungal therapy
-   MIC testing and therapeutic drug monitoring (TDM) are important tools used to address pharmacodynamic and pharmacokinetic variability of antifungals.
-   Knowledge of PK/PD can be used to individualise patient drug selection and dosing to improve the probability of a positive microbiological/clinical outcome
-   Antifungal toxicities and drug interactions are common, and should be anticipated and managed individually depending on the treatment scenario and risks (e.g., acute vs. chronic infections)

## References

<br>
